|
SCH 503034 HCV Protease Inhibitor Plus PEG-IFN a-2b in HCV-1 PEG-IFN a-2b Non-responders: Phase 1b Results
|
|
|
Reported by Jules Levin
These are the study results presented by S Zeuzem at AASLD Nov 2005 for the phase I 14 day study of the combination of SCH 503034 plus Peg-IFN a-2b. A larger phase II study is ongoing exploring several dosing regimens including a higher dose of 800 mg three times daily.
S Zeuzem1, C C Sarrazin1, F Wagner2, R Rouzier3, N Forestier1, s Gupta4, M Hussain, A Shah4, D Cutler4, J Zhang4
1Saarland University Hospital, Homburg, Germany
2PAREXEL International GmbH, berlin, germany
3Centre Cap, Montellier, france
4Schering-Plough Research Institute, Kenilworth, NJ, USA
![picture-1.gif](../images/031706/picture-1.gif)
![Evasion-2.gif](../images/031706/Evasion-2.gif)
![Picture-3.gif](../images/031706/Picture-3.gif)
![Picture-4.gif](../images/031706/Picture-4.gif)
![Picture-5.gif](../images/031706/Picture-5.gif)
![Picture-6.gif](../images/031706/Picture-6.gif)
![Picture-7.gif](../images/031706/Picture-7.gif)
|
|
|
|
|
|
|